Brief: Optiscan Imaging Signs Agreement With Long Grove Pharmaceuticals
23/06/2025 02:37
June 23 (Reuters) - Optiscan Imaging Ltd OIL.AX: SIGNS AGREEMENT WITH LONG GROVE PHARMACEUTICALS UNDER DEAL, COS TO DEVELOP NEW INTENDED USES FOR LONG GROVE'S INTRAVENOUS FLUORESCEIN SODIUM CONTRAST AGENT Further company coverage: OIL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Optiscan Imaging
See all newsBrief: Optiscan Imaging Lodges US FDA Dossier For Inspecta For Veterinary Market
Australia's Optiscan Imaging rises on deal with Australian Clinical Labs
Brief: Optiscan Imaging Enters Strategic Collaboration With Australian Clinical Labs
Brief: Optiscan Imaging Launches A$17.75M Entitlement Offer
Australia's Optiscan Imaging rises on collaboration with US-based firm